Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia

Raj Bhayadia1, Kathrin Krowiorz1, Nadine Haetscher1

  • 1Raj Bhayadia, Razan Jammal, Stephan Emmrich, Jan Fiedler, Adrian Schwarzer, Michael Heuser, Michelle Ng, Dirk Heckl, and Thomas Thum, Hannover Medical School, Hannover; Raj Bhayadia, Michelle Ng, and Jan-Henning Klusmann, University of Halle, Halle; Kathrin Krowiorz, Arefeh Rouhi, Konstanze Döhner, Hartmut Döhner, and Florian Kuchenbauer, University Hospital of Ulm, Ulm; Nadine Haetscher, Susanne Wingert, Sabrina Bothur, and Michael A. Rieger, Goethe University Frankfurt, Frankfurt; Sabrina Bothur and Michael A. Rieger, German Cancer Consortium, and German Cancer Research Center, Heidelberg; Dirk Reinhardt, University Hospital Essen, Essen, Germany; Askar Obulkasim, C. Michel Zwaan, and Maarten Fornerod, Erasmus MC/Sophia Children's Hospital, Rotterdam; Marry van den Heuvel Eibrink, Prinses Maxima Center for Pediatric Oncology, Utrecht, the Netherlands; Tobias Mätzig and R. Keith Humphries, Terry Fox Laboratory, Vancouver, Canada; and Thomas Thum, National Heart and Lung Institute, Imperial College London, London, United Kingdom.

Insights

MicroRNA-193b (miR-193b) acts as a tumor suppressor in acute myeloid leukemia (AML). Restoring miR-193b expression halts AML progression and improves prognosis by targeting key signaling pathways.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are crucial regulators in cancer development.
  • Dysregulated miRNAs contribute to the pathogenesis and aggressiveness of acute myeloid leukemia (AML).
  • miR-193b's role in hematopoietic stem-cell self-renewal and AML progression requires elucidation.

Purpose of the Study:

  • To investigate the effect of miR-193b on the progression and prognosis of AML.
  • To explore the tumor-suppressive function of miR-193b in AML.
  • To identify the molecular mechanisms underlying miR-193b's action in AML.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) to profile miR-193b expression in pediatric and adult AML cohorts.
  • In vitro and in vivo studies using human AML blasts, patient-derived xenografts, and miR-193b knockout mice.
  • Analysis of signaling pathways, including KIT-RAS-RAF-MEK-ERK (MAPK) and cell cycle regulators.

Main Results:

  • miR-193b exhibits endogenous tumor-suppressive functions in the hematopoietic system.
  • Downregulation of miR-193b-3p was observed in pediatric and adult AML subgroups, correlating with poor prognosis.
  • Restoring miR-193b impaired leukemic engraftment in vivo and inhibited AML growth in vitro and in xenografts.
  • miR-193b induced apoptosis and G1/S-phase arrest by targeting MAPK signaling and CCND1.

Conclusions:

  • miR-193b functions as a tumor suppressor in AML, independent of patient age or genetics.
  • Restoring miR-193b expression demonstrates significant antileukemic efficacy by inhibiting the MAPK pathway.
  • Targeting miR-193b offers a promising strategy to prevent AML resistance mechanisms and improve therapeutic outcomes.

Related Concept Videos

Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.1K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
7.0K
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic01:26

Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic

Healthcare-associated infections (HAIs) occur in a healthcare facility while a person receives care for another ailment. This category also includes work-related infections among healthcare staff.
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
5.9K